{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:04:09Z","timestamp":1763755449821,"version":"3.45.0"},"reference-count":38,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2003,7,1]]},"DOI":"10.1188\/03.cjon.403-408","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:44:00Z","timestamp":1187865840000},"page":"403-408","source":"Crossref","is-referenced-by-count":26,"title":["Advances in Supportive Care of Patients With Cancer and Bone Metastases: Nursing Implications of Zoledronic Acid"],"prefix":"10.1188","volume":"7","author":[{"given":"Cathy","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Swift","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Goode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois","family":"Doane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Badia, X., Diez-Perez, A., Alvarez-Sanz, C., Diaz-Lopez, B., Diaz-Curiel, M., Guillen, F., et al. (2001). Measuring quality of life in women with vertebral fractures due to osteoporosis: A comparison of the OQLQ and QUALEFFO. <i>Quality of Life Research<\/i>, <i>10<\/i>, 307-317.","DOI":"10.1023\/A:1012200508847"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Barnett, M.L. (1999). Hypercalcemia. <i>Seminars in Oncology Nursing<\/i>, <i>15<\/i>, 190-201.","DOI":"10.1016\/S0749-2081(99)80007-2"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Belch, A.R., Bergsagel, D.E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., et al. (1991). Effect of daily etidronate on the osteolysis of multiple myeloma. <i>Journal of Clinical Oncology<\/i>, <i>9<\/i>, 1397-1402.","DOI":"10.1200\/JCO.1991.9.8.1397"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Berenson, J.R. (2001). Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials. <i>Seminars in Oncology<\/i>, <i>28<\/i>, 25-34.","DOI":"10.1016\/S0093-7754(01)90262-3"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., et al. (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. <i>New England Journal of Medicine<\/i>, <i>334<\/i>, 488-493.","DOI":"10.1056\/NEJM199602223340802"},{"key":"E00006","unstructured":"Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., et al. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. <i>Journal of Clinical Oncology<\/i>, <i>16<\/i>, 593-602."},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., et al. (2001). Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A doubleblind, randomized dose-response study [published erratum appears in <i>Cancer<\/i>, <i>91<\/i>, p. 1956]. <i>Cancer<\/i>, <i>91<\/i>, 1191-1200.","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0"},{"key":"E00008","unstructured":"Body, J.J., Bartl, R., Burckhardt, P., Delmas, P.D., Diel, I.J., Fleisch, H., et al. (1998). Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. <i>Journal of Clinical Oncology<\/i>, <i>16<\/i>, 3890-3899."},{"key":"E00009","unstructured":"Bryce, C.J., Prior, J., Sill, K., Speers, C., Coldman, A., Norris, B., et al. (2002). Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients? [Abstract 270]. <i>Proceedings of the American Society of Clinical Oncology<\/i>, <i>21<\/i>, 68a. Coleman, R.E. (1997). Skeletal complications of malignancy. <i>Cancer<\/i>, <i>80<\/i>, 1588-1594."},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"DesHarnais Castel, L., Bajwa, K., Markle, J.P., Timbie, J.W., Zacker, C., & Schulman, K.A. (2001). A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. <i>Supportive Care in Cancer<\/i>, <i>9<\/i>, 545-551.","DOI":"10.1007\/s005200100249"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Fulfaro, F., Casuccio, A., Ticozzi, C., & Ripamonti, C. (1998). The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. <i>Pain<\/i>, <i>78<\/i>, 157-169.","DOI":"10.1016\/S0304-3959(98)00135-3"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Green, J.R., M\u00fcller, K., & Jaeggi, K.A. (1994). Preclinical pharmacology of CGP 42\u00b4446, a new, potent, heterocyclic bisphosphonate compound. <i>Journal of Bone and Mineral Research<\/i>, <i>9<\/i>, 745-751.","DOI":"10.1002\/jbmr.5650090521"},{"key":"E00013","unstructured":"Hortobagyi, G.N., Theriault, R.L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., et al. (1998). Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. <i>Journal of Clinical Oncology<\/i>, <i>16<\/i>, 2038-2044."},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., et al. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. <i>New England Journal of Medicine<\/i>, <i>335<\/i>, 1785-1791.","DOI":"10.1056\/NEJM199612123352401"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Hughes, D.E., Wright, K.R., Uy, H.L., Sasaki, A., Yoneda, T., Roodman, G.D., et al. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. <i>Journal of Bone and Mineral Research<\/i>, <i>10<\/i>, 1478-1487.","DOI":"10.1002\/jbmr.5650101008"},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Koeberle, D., Bacchus, L., Thuerlimann, B., & Senn, H.J. (1999). Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. <i>Supportive Care in Cancer<\/i>, <i>7<\/i>, 21-27.","DOI":"10.1007\/s005200050218"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Lipton, A., Theriault, R.L., Hortobagyi, G.N., Simeone, J., Knight, R.D., Mellars, K., et al. (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long-term follow-up of two randomized, placebo-controlled trials. <i>Cancer<\/i>, <i>88<\/i>, 1082-1090.","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z"},{"key":"E00018","unstructured":"Machado, C.E., & Flombaum, C.D. (1996). Safety of pamidronate in patients with renal failure and hypercalcemia. <i>Clinical Nephrology<\/i>, <i>45<\/i>, 175-179."},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D., et al. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. <i>Journal of Clinical Oncology<\/i>, <i>19<\/i>, 558-567.","DOI":"10.1200\/JCO.2001.19.2.558"},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Menssen, H.D., Sakalova, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., et al. (2002). Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. <i>Journal of Clinical Oncology<\/i>, <i>20<\/i>, 2353-2359.","DOI":"10.1200\/JCO.2002.02.032"},{"key":"E00021","unstructured":"Novartis Pharmaceuticals Corporation. (2002a). Aredia\u00ae [package insert]. East Hanover, NJ: Author."},{"key":"E00022","unstructured":"Novartis Pharmaceuticals Corporation. (2002b). Outpatient infusion with Zometa\u00ae (zoledronic acid for injection). For U.S. residents only. Retrieved October 21, 2002, from <a target=\"_blank\" href='http:\/\/www.us.zometa.com\/hcp\/productinfo\/infusioninstructions.jsp'>http:\/\/www.us.zometa.com\/hcp\/productinfo\/infusioninstructions.jsp<\/a>"},{"key":"E00023","unstructured":"Novartis Pharmaceuticals Corporation. (2002c). Zometa\u00ae [package insert]. East Hanover, NJ: Author."},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Paterson, A.H., Powles, T.J., Kanis, J.A., McCloskey, E., Hanson, J., & Ashley, S. (1993). Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. <i>Journal of Clinical Oncology<\/i>, <i>11<\/i>, 59-65.","DOI":"10.1200\/JCO.1993.11.1.59"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Ripamonti, C., & Fulfaro, F. (2000). Malignant bone pain: Pathophysiology and treatments. <i>Current Review of Pain<\/i>, <i>4<\/i>, 187-196.","DOI":"10.1007\/s11916-000-0078-3"},{"key":"E00026","unstructured":"Rosen, L., Gordon, D., Tchekmedyian, S., Hirsh, V., Yanagihara, R., Coleman, R.E., et al. (2002). Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. <i>Proceedings of the American Society of Clinical Oncology<\/i>, <i>21<\/i>, 295a."},{"key":"E00027","unstructured":"Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., et al. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. <i>Cancer Journal<\/i>, <i>7<\/i>, 377-387."},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. <i>Journal of the National Cancer Institute<\/i>, <i>94<\/i>, 1458-1468.","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Siegal, T., Tiqva, P., & Siegal, T. (1985). Vertebral body resection for epidural compression by malignant tumors. Results of forty-seven consecutive operative procedures. <i>Journal of Bone and Joint Surgery. American Volume<\/i>, <i>67<\/i>, 375-382.","DOI":"10.2106\/00004623-198567030-00004"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Silverman, S.L., Minshall, M.E., Shen, W., Harper, K.D., & Xie, S. (2001). The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: Results from the Multiple Outcomes of Raloxifene Evaluation Study. <i>Arthritis Rheumatism<\/i>, <i>44<\/i>, 2611-2619.","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N"},{"key":"E00031","unstructured":"Small, E.J., Smith, M.R., Seaman, J.J., & Kowalski, M.O. (in press). A multicenter, randomized, placebo-controlled study of pamidronate disodium for the palliation of bone pain in men with advanced prostate cancer. <i>Journal of Clinical Oncology.<\/i> Smith, J.A., Jr. (1989). Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. <i>Journal of Urology<\/i>, <i>141<\/i>, 85-87."},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gl\u00fcck, S., Stewart, J.F., et al. (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. <i>Journal of Clinical Oncology<\/i>, <i>17<\/i>, 846-854.","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"E00033","unstructured":"Tripathy, D., Lazarev, A., Lichinitser, M.R., Decker, D., McLachlan, S.A., & Budde, M. (2002). Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases [Abstract 176]. <i>Proceedings of the American Society of Clinical Oncology<\/i>, <i>21<\/i>, 45a."},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Turner, S.L., Gruenewald, S., Spry, N., & Gebski, V. (2001). Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Metastron Users Group. <i>British Journal of Cancer<\/i>, <i>84<\/i>, 297-302.","DOI":"10.1054\/bjoc.2000.1610"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Vinholes, J.J., Purohit, O.P., Abbey, M.E., Eastell, R., & Coleman, R.E. (1997). Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. <i>Annals of Oncology<\/i>, <i>8<\/i>, 1243-1250.","DOI":"10.1023\/A:1008238422151"},{"key":"E00036","doi-asserted-by":"crossref","unstructured":"Vitale, G., Fonderico, F., Martignetti, A., Caraglia, M., Ciccarelli, A., Nuzzo, V., et al. (2001). Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. <i>British Journal of Cancer<\/i>, <i>84<\/i>, 1586-1590.","DOI":"10.1054\/bjoc.2001.1832"},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Watters, J., Gerrand, G., & Dodwell, D. (1996). The management of malignant hypercalcaemia. <i>Drugs<\/i>, <i>52<\/i>, 837-848.","DOI":"10.2165\/00003495-199652060-00005"},{"key":"E00038","unstructured":"Wong, R., & Wiffen, P.J. (2003). Bisphosphonates for the relief of pain secondary to bone metastases [Cochrane review]. In <i>Cochrane Library, Issue<\/i><i>1<\/i>, 2003. Oxford, UK: Update Software."}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/10J61N649872L670.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:53:08Z","timestamp":1763754788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/7\/4\/advances-supportive-care-patients-cancer-and-bone-metastases-nursing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["10J61N649872L670"],"URL":"https:\/\/doi.org\/10.1188\/03.cjon.403-408","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}